LMATHealthcare · Medical Instruments & SuppliesLMAT Stock Forecast: LeMaitre Vascular, Inc. Price Predictions for 2026-2027
The 9 Wall Street analysts covering LeMaitre Vascular, Inc. hold a median 12-month price target of $120 — +15.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
LMAT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores LeMaitre Vascular, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (92): The share price has been relatively steady.
Issuance (43): The company has been issuing shares or taking on financing, diluting existing holders.
Size (34): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own LeMaitre Vascular, Inc. — and when they’d sell — is the membership.
LMAT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LMAT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +15.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 June 2026 | Barrington Research | Maintains | Outperform | $120 |
| 6 May 2026 | Barrington Research | Maintains | Outperform | — |
| 6 May 2026 | Citizens | Maintains | Market Outperform | — |
| 6 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 26 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 26 Feb 2026 | Citizens | Maintains | Market Outperform | — |
| 26 Feb 2026 | Roth Capital | Reiterates | Buy | — |
| 26 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 20 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 7 Nov 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 5 Nov 2025 | Roth Capital | Reinstates | Buy | $108 |
| 15 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 23 Sept 2025 | Barrington Research | Maintains | Outperform | — |
| 6 Aug 2025 | Barrington Research | Upgrade | Outperform | — |
| 6 Aug 2025 | Cantor Fitzgerald | Maintains | Neutral | — |
| 22 July 2025 | Barrington Research | Reiterates | Market Perform | — |
| 28 Feb 2025 | Barrington Research | Downgrade | Market Perform | — |
| 28 Feb 2025 | Citizens Capital Markets | Maintains | Buy | — |
| 28 Feb 2025 | Lake Street | Maintains | Buy | — |
| 13 Feb 2025 | Wells Fargo | Initiates | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LMAT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
LeMaitre Vascular, Inc. (LMAT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 38.1×
- Price / sales
- 9.2×
- Price / book
- 5.8×
- EV / EBITDA
- 27.1×
Cheaper than 21% of US stocks
Cheaper than 15% of US stocks
Cheaper than 18% of US stocks
Cheaper than 10% of US stocks
- Revenue growth (YoY)
- 11.2%
- Earnings growth (YoY)
- 42.4%
- Gross margin
- 72.7%
- Operating margin
- 26.7%
- Net margin
- 24.3%
Higher than 58% of US stocks
Higher than 75% of US stocks
Higher than 85% of US stocks
Higher than 86% of US stocks
Higher than 85% of US stocks
- Return on equity
- 16.5%
- Return on assets
- 7.2%
- Dividend yield
- 1.0%
Higher than 77% of US stocks
Higher than 86% of US stocks
Higher than 22% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
LMAT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LMAT appears on the weeks it earns a place.
Frequently asked questions about LMAT stock
What is the LMAT stock price forecast for 2026-2027?
The 9 Wall Street analysts covering LeMaitre Vascular, Inc. have a median 12-month price target of $120, with estimates ranging from $102 to $135. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LMAT stock a buy right now?
Of the 9 analysts covering LeMaitre Vascular, Inc., 5 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LeMaitre Vascular, Inc. 91 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LMAT?
As at 1 Aug 2026, LeMaitre Vascular, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (92 of 100).
Will LMAT stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts implies +15.8% from the last close, and Ticker Nerd's factor model ranks LeMaitre Vascular, Inc. 91 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LMAT stock forecast for 2030?
No analyst covering LeMaitre Vascular, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LMAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $102 to $135 over the next 12 months.
How has LMAT stock performed over the past year?
LeMaitre Vascular, Inc. returned +29.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does LeMaitre Vascular, Inc. do?
LeMaitre Vascular Inc. develops, manufactures, and markets specialized medical devices and implants designed for vascular surgery and the treatment of peripheral vascular disease.
About LeMaitre Vascular, Inc.
LeMaitre Vascular Inc. develops, manufactures, and markets specialized medical devices and implants designed for vascular surgery and the treatment of peripheral vascular disease. The company offers a comprehensive portfolio of products across six key categories: aortic, arteriovenous access, cardiac, carotid, lower extremity, and neuro applications. Its product lines include allografts—cryopreserved human tissue grafts used in vascular reconstruction—embolectomy catheters for removing blood clots from arteries, thrombectomy catheters for venous thrombi removal, and various synthetic and biologic grafts and patches. LeMaitre also provides human tissue cryopreservation services. The company distributes its products globally through direct sales to hospitals in over 25 countries and through distributors in more than 70 countries across North America, Europe, and Asia-Pacific. Founded in 1986 and headquartered in Burlington, Massachusetts, LeMaitre serves vascular surgeons performing both open surgical procedures and minimally invasive interventions, with the majority of its revenue generated from the United States market.
CEO Mr. George W. LeMaitre · 646 employees · United States · https://www.lemaitre.com